PENTASA 1g PROLONGED-RELEASE GRANULES

2. What you need to know before taking Pentasa

Do not take Pentasa

• if you are allergic (hypersensitive)to mesalazineor any of the other ingredients of this medicine (see section 6)
• if you are allergicto other salicylates, e.g. aspirin
• if you have severe kidney and/or liver problems

Warnings and precautions

Consult your doctor or pharmacist before taking Pentasa:

• if you are allergic to sulfasalazine(risk of salicylate allergy)
• if you currently have or have had kidney or liver function impairment
• if you have a disease that may make you prone to bleeding
• if you have an active peptic ulcer(stomach or duodenal ulcer)
• if you are on treatmentthat may affect kidney function, e.g. non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin
• if you have lung problems, asthma in particular
• treatment should be discontinued immediately in case of abdominal cramps, abdominal pain, fever, severe headache, and rash
• kidney stones may occur with the use of mesalazine. Symptoms include pain in the sides of the abdomen and blood in the urine. Make sure to drink a sufficient amount of liquid during treatment with mesalazine.
• If you have ever suffered from a severe skin rash, skin peeling, blisters, or sores in the mouth after using mesalazine.

Mesalazine may cause a discoloration of the urine to a reddish-brown color after contact with sodium hypochlorite bleach in the toilet water. This is a chemical reaction between mesalazine and bleach and is harmless.

Be careful with mesalazine:

Severe skin reactions, including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SSJ), and toxic epidermal necrolysis (TEN), have been observed with mesalazine treatment. Stop taking mesalazine and seek medical attention immediately if you notice any of the symptoms related to these severe skin reactions described in section 4.

While you are on treatment with this medicine, your doctor will normally perform blood and urine tests to monitor your kidney function, especially at the start of treatment.

Interaction of Pentasa with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. This is especially important if you are taking any of the following medicines:

• azathioprine(used after transplants or to treat autoimmune diseases)
• 6-mercaptopurine or thioguanine(chemotherapy, used to treat leukemia)
• certain medicines that inhibit blood coagulation (medicines for thrombosis or to thin the blood)

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, or think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

There is limited experience with the use of mesalazine during pregnancy and breastfeeding.

Blood disorders have been observed in newborns of mothers treated with this medicine. Newborns may develop allergic reactions after breastfeeding, e.g. diarrhea. If the newborn has diarrhea, breastfeeding should be discontinued.

Driving and using machines:

This medicine is not known to affect the ability to drive or use machines.

3. How to take Pentasa

Follow the instructions for administration of this medicine exactly as prescribed by your doctor or pharmacist. If you are unsure, consult your doctor or pharmacist again.

Adults:

To treat a flare-up of colitis,your doctor will normally prescribe a dose of up to 4g of mesalazine per day, which can be taken either once daily or divided into two doses. It can be taken as two Pentasa 2g sachets once daily.

Pentasa 1g prolonged-release granules can also be used to provide the dose that best suits you.

To help you stay free of further flare-ups, your doctor may prescribe 2g of mesalazine per day, administered as one Pentasa 2g sachet or two Pentasa 1g sachets once daily.

Children and adolescents (aged 6 years and above):

For children and adolescents, the dose will be calculated by your doctor based on body weight. The recommended dose in children and adolescents with a body weight of up to 40kg will be half the usual recommended dose in adults, and for those with a body weight above 40kg, the dose will be the same as the usual recommended dose in adults.

You should take the granules orally (by mouth),immediately after opening the sachet, as described below. Do not chew the granules.

1. Open the sachet.
2. Pour the contents of the sachet onto the tongue and swallow the granules immediately with water or orange juice, making sure none remain in the mouth.

Or

1. Mix the entire contents of the sachet with yoghurt. Swallow immediately without chewing the granules.

If you take more Pentasa sachets than you should

In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone 91 562 04 20, stating the medicine and the amount taken.

If you forget to take Pentasa sachets

If you have forgotten to take a dose, take it as soon as you remember, and then take the next dose at the usual time. Do not take a double dose to make up for the forgotten dose.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, Pentasa sachets can cause side effects, although not everybody gets them.

Very rare cases of severe allergic reactions (including severe skin reactions that can affect the skin as a protective barrier of the body) have been reported. The allergic reaction could lead to swelling of the face and neck and/or difficulty breathing or swallowing (angioedema). If this happens, contact your doctor or emergency services immediately.

Stop taking mesalazine and seek medical attention immediately if you experience any of the following symptoms: reddish patches, or circular or coin-shaped patches on the chest, often with central blisters, skin peeling, ulcers in the mouth, throat, nose, genitals, and eyes, generalized rash, fever, and swollen lymph nodes. These severe skin reactions are often preceded by fever or flu-like symptoms.

The following side effects are common(affect 1 to 10 users in 100):

• diarrhea
• abdominal pain
• nausea
• vomiting
• headache
• skin rash
• flatulence (gas)

The following side effects are rare(affect 1 to 10 users in 1,000):

• inflammation of some areas of the heart (myocarditis and pericarditis) that can cause difficulty breathing and chest pain or palpitations (rapid or irregular heartbeat)
• inflammation of the pancreas (including symptoms of back and/or stomach pain)
• increased amylase (an enzyme that helps digest carbohydrates)
• dizziness
• increased sensitivity of the skin to sunlight and ultraviolet light (photosensitivity)

The following side effects are very rare(affect less than 1 user in 1,000):

• anemia and other blood disorders (decrease in the number of certain blood cells, which can cause unexplained bleeding, bruising, fever, or sore throat)
• liver disorders (symptoms include jaundice (yellowing of the skin and/or eyes) and/or pale stools)
• kidney disorders (symptoms include blood in the urine and/or edema (swelling due to increased fluid))
• peripheral neuropathy (a condition that affects the nerves of the hands and feet, including symptoms of tingling and numbness)
• allergic and fibrotic lung reactions, inflammation of the lining of the lungs or scarring of the lung (symptoms include cough, bronchospasm, chest discomfort or pain when breathing, difficulty breathing, bloody or excessive sputum)
• Pancolitis (a type of inflammatory bowel disease (IBD) that affects the entire inner lining of the colon)
• hair loss (this is reversible)
• muscle or joint pain
• inflammation that can affect several parts of the body, such as joints, skin, kidneys, heart, etc. (symptoms include painful joints, fatigue, fever, unexplained or unusual bleeding (e.g. nosebleeds), bruising, purple discoloration of the skin, spots under the skin (including severe skin reactions and severe burns that can affect the skin as a protective barrier of the body))
• fluid accumulation around the heart (pericardial effusion) that can cause chest pain or pressure
• change in urine color
• semen with low sperm concentration (oligospermia) (this is reversible)
• severe diarrhea and abdominal pain due to an allergic reaction to this medicine in the intestine
• occasional allergic reactions and fever may occur

Frequency not known (cannot be estimated from the available data)

• kidney stones and associated kidney pain (see also section 2).

Isolated cases of benign intracranial hypertension (increase in fluid around the brain) have been reported in adolescents. Symptoms include headache, nausea, vomiting, and/or visual or auditory disturbances.

Reporting of side effects:

If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Medicines and Healthcare Products Agency (AEMPS) website: http://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Pentasa

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the packaging and on the aluminum sachet. The expiry date is the last day of the month stated.

This medicine does not require any special storage conditions.

Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to your pharmacist. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Contents of the pack and other information

Composition of Pentasa sachets

The active substance is mesalazine.

Each sachet contains 1g of mesalazine.

The other ingredients are ethylcellulose and povidone

Appearance of the product and pack contents

This medicine contains prolonged-release granules. The granules are white or pale brown and cylindrical in shape.

This medicine is available in aluminum sachets in packs of:

1g sachets: 50 or 100

Marketing authorization holder

FERRING S.A.U

C/ del Arquitecto Sánchez Arcas 3, 1º

Madrid 28040

• Spain

Manufacturer

Ferring GmbH

Wittland 11

D-24109 Kiel

Germany

This medicine is authorized in the Member States of the European Economic Area under the following names:

Quintasa Sachets: Denmark

Pentasa Sachets: Cyprus, Germany, Greece, Ireland, Spain, Sweden, United Kingdom (Northern Ireland)

Pentasa: Slovenia

The last revision of this leaflet was in January 2023.

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) http://www.aemps.gob.es/